 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
| «123456 |
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder (clinicaltrials.gov) - Sep 14, 2017
P2, N=50, Completed, Sponsor: Actelion
Active, not recruiting --> Completed
- |||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder (clinicaltrials.gov) - Jul 2, 2017
P2, N=360, Completed, Sponsor: Actelion
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Enrollment closed: Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder (clinicaltrials.gov) - Jun 9, 2017
P2, N=50, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - May 4, 2017
P1, N=40, Completed, Sponsor: Actelion
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Enrollment closed, Enrollment change: Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder (clinicaltrials.gov) - Apr 20, 2017
P2, N=360, Active, not recruiting, Sponsor: Actelion
Active, not recruiting --> Completed Recruiting --> Active, not recruiting | N=300 --> 360
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P1 trial: A Study of ACT-541468 in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - Apr 5, 2017
P1, N=40, Recruiting, Sponsor: Actelion
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam (clinicaltrials.gov) - Feb 28, 2017
P1, N=20, Completed, Sponsor: Actelion
Recruiting --> Active, not recruiting | N=300 --> 360 Recruiting --> Completed
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P1 trial: A Clinical Study to Investigate the Potential Interactions Between Food and ACT-541468 and Between ACT-541468 and Midazolam (clinicaltrials.gov) - Jan 11, 2017
P1, N=20, Recruiting, Sponsor: Actelion
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Enrollment open: Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder (clinicaltrials.gov) - Dec 7, 2016
P2, N=50, Recruiting, Sponsor: Actelion
Recruiting --> Completed Not yet recruiting --> Recruiting
- |||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Enrollment open: Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder (clinicaltrials.gov) - Oct 25, 2016
P2, N=300, Recruiting, Sponsor: Actelion
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P1 trial: A Single Ascending Dose Study of ACT-541468 in Healthy Male Subjects (clinicaltrials.gov) - Sep 29, 2016
P1, N=40, Completed, Sponsor: Actelion
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P2 trial: Efficacy and Safety of ACT-541468 in Elderly Subjects With Insomnia Disorder (clinicaltrials.gov) - Jul 23, 2016
P2, N=50, Not yet recruiting, Sponsor: Actelion
- ||||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P2 trial: Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder (clinicaltrials.gov) - Jul 20, 2016
P2, N=300, Not yet recruiting, Sponsor: Actelion
- ||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects (clinicaltrials.gov) - Mar 1, 2016
P1, N=84, Completed, Sponsor: Actelion
Not yet recruiting --> Recruiting Recruiting --> Completed
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Trial completion: Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects (clinicaltrials.gov) - Feb 23, 2016
P1, N=14, Completed, Sponsor: Actelion
Recruiting --> Completed Not yet recruiting --> Completed
- ||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P1 trial: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects (clinicaltrials.gov) - Oct 22, 2015
P1, N=84, Recruiting, Sponsor: Actelion
- ||| Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
Enrollment open: A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects (clinicaltrials.gov) - Oct 22, 2015
P1, N=84, Recruiting, Sponsor: Actelion
Not yet recruiting --> Completed Not yet recruiting --> Recruiting
- | Quviviq (daridorexant) / Idorsia, Mochida, Syneos Health, Sosei
New P1 trial: Pharmacokinetic Interaction Between Diltiazem and ACT-541468 in Healthy Subjects (clinicaltrials.gov) - Aug 18, 2015
P1, N=14, Not yet recruiting, Sponsor: Actelion